{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:59:28Z","timestamp":1791233968779,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011088","name":"University College London Hospital's Charitable Foundation","doi-asserted-by":"publisher","award":["P83624\/1348"],"award-info":[{"award-number":["P83624\/1348"]}],"id":[{"id":"10.13039\/100011088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204998\/Z\/16\/Z"],"award-info":[{"award-number":["204998\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2024.06.010","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:50:47Z","timestamp":1720281047000},"page":"663-673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patients\u2019 Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-7508","authenticated-orcid":false,"given":"Martin J.","family":"Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesfin","family":"Genie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Dudderidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Innominato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Klimowska-Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Madaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ostler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Paisey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayanan","family":"Srihari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal Thippu","family":"Jayaprakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verity","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.06.010_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2024.06.010_b0010","unstructured":"The National Prostate Cancer Audit (NPCA). Patient and tumour characteristics associated with metastatic prostate cancer at diagnosis in England 2022. London: NPCA; 2022."},{"key":"10.1016\/j.euo.2024.06.010_b0015","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdy071","article-title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","volume":"29","author":"Vale","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.06.010_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2024.06.010_b0030","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.eururo.2021.01.029","article-title":"Radical treatment without cure: Decision-making in oligometastatic prostate cancer","volume":"79","author":"Connor","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.010_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.28002","article-title":"Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients","volume":"133","author":"Lilleby","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2024.06.010_b0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10555-012-9373-9","article-title":"The metastatic niche and stromal progression","volume":"31","author":"Sleeman","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.euo.2024.06.010_b0050","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.06.010_b0055","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.06.010_b0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2024.06.010_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048996","article-title":"Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study","volume":"11","author":"Connor","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2024.06.010_b0075","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"10.1016\/j.euo.2024.06.010_b0080","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.euo.2024.06.010_b0085","unstructured":"NHS England. Clinical commissioning policy statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone na\u0131ve metastatic prostate cancer. Redditch, UK: NHS England; 2016."},{"key":"10.1016\/j.euo.2024.06.010_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"Johnson","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2024.06.010_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042953","article-title":"Additional treatments to the local tumour for metastatic prostate cancer-assessment of novel treatment algorithms (IP2-ATLANTA): Protocol for a multicentre, phase II randomised controlled trial","volume":"11","author":"Connor","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2024.06.010_b0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JU.0000000000000754","article-title":"Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study","volume":"204","author":"Watson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.06.010_b0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","article-title":"Discrete choice experiments in health economics: past, present and future","volume":"37","author":"Soekhai","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2024.06.010_b0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2024.06.010_b0115","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hec.1739","article-title":"Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations","volume":"21","author":"Coast","year":"2012","journal-title":"Health Econ"},{"key":"10.1016\/j.euo.2024.06.010_b0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.euros.2021.10.003","article-title":"A systematic review of patients\u2019 values, preferences, and expectations for the treatment of metastatic prostate cancer","volume":"36","author":"Connor","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"suppl 1","key":"10.1016\/j.euo.2024.06.010_b0125","doi-asserted-by":"crossref","first-page":"i55","DOI":"10.1136\/qhc.0100055","article-title":"Use of discrete choice experiments to elicit preferences","volume":"10","author":"Ryan","year":"2001","journal-title":"Qual Health Care"},{"key":"10.1016\/j.euo.2024.06.010_b0130","first-page":"588","article-title":"ECOG: CHAARTED\u2013ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer","volume":"4","author":"Sweeney","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0135","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10198-018-0954-6","article-title":"How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity","volume":"19","author":"Quaife","year":"2018","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.euo.2024.06.010_b0140","unstructured":"US Food and Drug Administration. Patient preference information\u2013voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2016; 2017."},{"key":"10.1016\/j.euo.2024.06.010_b0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jval.2016.04.006","article-title":"Patient-focused benefit-risk analysis to inform regulatory decisions: The European Union perspective","volume":"19","author":"M\u00fchlbacher","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2024.06.010_b0150","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","article-title":"A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies","volume":"19","author":"Ho","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2024.06.010_b0155","unstructured":"Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. European Association of Urology (EAU); 2023."},{"key":"10.1016\/j.euo.2024.06.010_b0160","unstructured":"NHS England Clinical Commissioning. External beam radiotherapy for patients presenting with hormone sensitive, low volume metastatic prostate cancer at the time of diagnosis [P200802P] (URN: 1901). London: NHS England; 2020."},{"key":"10.1016\/j.euo.2024.06.010_b0165","unstructured":"ClinicalTrials.gov. Additional treatments to the local tumour for metastatic prostate cancer: assessment of novel treatment algorithms (IP2-ATLANTA). NCT03763253. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03763253."},{"key":"10.1016\/j.euo.2024.06.010_b0170","unstructured":"ClinicalTrials.gov. Standard systemic therapy with or without definitive treatment in treating participants with metastatic prostate cancer (SWOG 1802). NCT03678025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03678025."},{"key":"10.1016\/j.euo.2024.06.010_b0175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bju.15669","article-title":"Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial","volume":"130","author":"Sooriakumaran","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.06.010_b0180","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.3390\/cancers13225636","article-title":"Health-related quality of life following cytoreductive radical prostatectomy in patients with de-novo oligometastatic prostate cancer","volume":"13","author":"Chaloupka","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2024.06.010_b0185","first-page":"650","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer. The ORIOLE phase 2 randomized clinical trial. JAMA","volume":"6","author":"Phillips","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0195","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2020.12.015","article-title":"Patient satisfaction and regret after robot-assisted radical prostatectomy: a decision regret analysis","volume":"149","author":"Lindsay","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.06.010_b0200","article-title":"Shared decision-making: summary of NICE guidance","volume":"373","author":"Carmona","year":"2021","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2024.06.010_b0205","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/1472-6947-13-S2-S12","article-title":"Establishing the effectiveness of patient decision aids: key constructs and measurement instruments","volume":"13 Suppl 2","author":"Sepucha","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.euo.2024.06.010_b0210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/PPA.S221897","article-title":"Using a discrete-choice experiment in a decision aid to nudge patients towards value-concordant treatment choices in rheumatoid arthritis: a proof-of-concept study","volume":"14","author":"Hazlewood","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.euo.2024.06.010_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-016-1536-5","article-title":"Using discrete choice experiments as a decision aid in total knee arthroplasty: study protocol for a randomised controlled trial","volume":"17","author":"Dowsey","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.euo.2024.06.010_b0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-066379","article-title":"Using a discrete choice experiment to develop a decision aid tool to inform the management of persistent pain in pharmacy: a protocol for a randomised feasibility study","volume":"12","author":"Lor\u00eda-Rebolledo","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2024.06.010_b0225","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.06.010_b0230","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.06.010_b0235","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study","volume":"27","author":"Priv\u00e9","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:26:42Z","timestamp":1762630002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2588931124001585"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients\u2019 Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}